期刊文献+

子宫内膜癌分子标志物与临床病理特征关系的研究 被引量:8

Study of the relationships between the biomarkers and the clinicopathologic features in endometrial carcinoma
下载PDF
导出
摘要 目的探讨子宫内膜癌中ER、PR、PTEN、p53及Ki-67的表达与临床、病理特征的关系。方法收集200例原发性子宫内膜癌患者的临床病理资料,对其ER、PR、PTEN、p53及Ki-67表达情况进行统计学分析。结果①子宫内膜癌病例中,ER、PR、PTEN、p53的阳性表达率分别为86.5%、85.5%、82.1%和49.2%;Ki-67在癌灶中的阳性表达率为4%~95%,平均为46.9%。②妊娠次数与PR阳性表达呈负相关(r=-0.191,P=0.007),而发病年龄、分娩次数与p53阳性表达呈正相关(r=0.184,P=0.041;r=0.255,P=0.004)。③子宫内膜样腺癌ER、PR、p53阳性率与其他类型子宫内膜癌比较,差异有统计学意义(P<0.01)。④ER阳性表达与手术病理分期呈负相关(r=-0.155,P=0.028),其中Ⅰ期患者ER阳性率高于Ⅱ期及以上患者(P=0.032)。⑤ER、PR阳性表达与组织学分级呈负相关(r=-0.217,P=0.002;r=-0.317,P=0.000),但p53、Ki-67表达与其呈正相关(r=0.327,P=0.000;r=0.465,P=0.000)。⑥ER阳性表达与肌层浸润深度呈负相关(r=-0.142,P=0.046),在有无深肌层浸润上ER、PR表达率均有统计学意义(P<0.05)。结论对子宫内膜活检组织进行分子标志物的分子特征检测,有助于指导临床。 Objective To explore the relationships between the expressions of biomarkers ER, PR, PTEN, p53, Ki- 67 and the elinicopathologic features in endometrial carcinoma. Methods The data of clinical characteristics, pathological type, histological grade, and the expression of biomarkers were analyzed in 200 patients with primary endometrial carcinoma. Results ① In the cases of endometrial carcinoma, the expression rates of ER, PR, PTEN, p53 were 86.5%, 85.5%, 82.1%, and 49.2%, respectively. The expression level of Ki- 67 in the tumor tissues was from 4% to 95% (mean 46.9%). ② A negative correlation was observed between the number of the gravidity, and the expression of PR (P=0. 007, r= - 0. 191), while age and parity were in positive correlation with the expression of p53 (P=0. 041, r=0. 184; P=0. 004, r=0. 255).③ The expression rates of ER, PR and p53 in the endometrioid carcinoma showed significant differences comparing with other histologic types (P〈0. 01).④ A negative correlation was found between the expression of ER and the FIGO staging (P=0. 028, r=-0. 155). The positive rate of ER in the cases with stage I was higher than that in cases with stage Ⅱ and above (P=0. 032). ⑤ A negative correlation was found between the tumor differentiation and the expression of ER, PR (P=0. 002, r=- 0. 217; P=0. 000, r= - 0. 317), however, a positive correlation was detected between the grade with the expression of p53, Ki - 67 (P=0. 000, r=0. 327; P=0. 000, r=0. 465). ⑥ A negative correlation was observed between the depth of myometrial invasion and the positive rate of ER (P=0. 046, r= - 0. 142). There were significantly different in expression rates of ER, PR between the cases whether the cancer invaded the deep myometrium or not (P〈0. 05). Conclusions The molecular characteristic of the endometrial carcinoma detected by IHC technology from the preoperative samples may be benefit for the patient management.
出处 《中国妇产科临床杂志》 2009年第3期189-192,共4页 Chinese Journal of Clinical Obstetrics and Gynecology
基金 985Ⅱ期妇产科疾病的基础与临床研究(985-2-015-24)基金资助
关键词 子宫内膜癌 雌激素受体 孕激素受体 免疫组织化学 endometrial carcinoma estrogen receptor progestin receptor immunohistochemistry
  • 相关文献

参考文献2

二级参考文献21

  • 1Gruber T, Dare AO, Balos LL, et al. Multiple meningiomas arising during long-term therapy with the progesterone agonist megestrol acetate. Case report. J Neurosurg,2004, 100:328-331.
  • 2Makarov OV, Sergeev PV, Sviridov NK, et al. Effect of gestagen therapy on clinical and biochemical parameters in patients with atypical endometrial hyperplasia. Vopr Onkol,2000,46:570-573.
  • 3Nola M, Jukic S, Ilic-Forko J, et al. Effects of tamoxifen on steroid hormone receptors and hormone concertration and the results of DNA analysis bu flow cytometry in endometrial carcinoma. Gynecol Oncol,1999,72:331-336.
  • 4Jobo T, Kawaguchi M, Imai M, et al. Treatment for complex atypical hyperplasia of the endometrium. Eur J Gynaecol Oncol,2001,22:365-368.
  • 5Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol,1999,17:1736-1744.
  • 6Imai M, Jobo T, Sato R, et al. Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol,2001,22:217-220.
  • 7Mikuta JJ. International Federation of Gynecology and Obstertrics staging of endometrial cancer 1988. Cancer, 1993, 71:1460-1463.
  • 8von Minckwitz G, Loibl S, Brunnert K, et al. Adjuvant endocrine treatment with medroxyprogesterone acetate or tamoxifen in stage I and II endometrial cancer--a multicentre, open, controlled, prospectively randomised trial. Eur J Cancer,2002,38:2265-2271.
  • 9Vishnevsky AS, Bokhman YaV, Loutfi G. Favourable influence of adjuvant hormone therapy by oxyprogesterone caproate (OPC) and by its combination with tamoxifen on 5-year survival rate of surgical and combined treatment of primary endometrial carcinoma patients. Eur J Gynaecol Oncol,1993,14:150-153.
  • 10Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol,2004,92:10-14.

共引文献31

同被引文献64

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部